Making Getting Skinny Taste Good: Cava CEO On The GLP-1 Boom

Cava CEO Brett Schulman said GLP-1 weight-loss drugs are changing customer ordering behavior, including smaller portions, adults purchasing kids meals, and greater demand for protein-focused and Mediterranean-style options. The article provides no financial figures or quantified sales impact, but highlights a potentially relevant shift in restaurant consumer preferences.